Perrigo Cuts 2026 Core EPS Outlook to $2.15-$2.35 on Soft Europe, Flags $275M-$375M Infant Formula Impairment
PRGO sits 75% above its 52-week low of $9.225.
Summary
Perrigo's Q3 swung to a $(0.10) reported loss, and management cut full-year Core adjusted EPS guidance to $2.15-$2.35 from $2.25-$2.55, citing softer retailer orders and weak Europe. The Infant Formula sale will also trigger a $275M-$375M impairment in Q4.
Key Events · Earnings and Guidance · PRGO
-
Q3 Swings to Reported Loss
Reported diluted EPS was $(0.10) versus $0.09 a year ago; All In adjusted EPS fell 25.0% to $0.60 from $0.80. Net sales declined 5.2% to $989 million.
-
Full-Year Guidance Cut
Core adjusted EPS outlook lowered to $2.15-$2.35 from $2.25-$2.55, and Core organic net sales growth now seen at (3.8)% to (2.7)% versus the prior (3.0)% to 1.0%.
-
Infant Formula Impairment Ahead
The pending divestiture to MeridianMade for up to $175 million ($40 million upfront cash) is expected to produce a $275.0 million to $375.0 million impairment loss in Q4 2026 when measured as held for sale.
-
Leverage Still Elevated
Total debt was $3.3 billion against $437 million of cash at September 26, 2026, with net leverage guided to approximately 4.0 times adjusted EBITDA.
Analysis · PRGO · Life Sciences
Sales for the quarter were roughly in line ($989M vs $987.2M consensus), but the profit picture deteriorated: reported diluted EPS swung to a $(0.10) loss from $0.09, and All In adjusted EPS fell 25% to $0.60. More important is the reset underneath. Management cut Core adjusted EPS guidance to $2.15-$2.35 from $2.25-$2.55 and now expects Core organic sales to decline 3.8%-2.7% versus a prior range that reached flat-to-up. The causes are named: more cautious retailer inventory positioning ahead of cough and cold season, and continued European consumer weakness. Layered on top is a $275M-$375M impairment on the Infant Formula business when it is marked held-for-sale in Q4, a real hit to book equity even though it is non-cash. Against $3.3B of total debt and roughly 4.0x net leverage, the $40M upfront cash from that divestiture does little to deleverage on its own.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRGO was trading at $16.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.23 to $20.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.